Primitive neuroectodermal tumour – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Primitive neuroectodermal tumour – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of ONC206 for children and young adults with newly diagnosed or recurrent diffuse midline glioma and other recurrent brain tumors https://clinicaltrials.eu/trial/study-of-onc206-for-children-and-young-adults-with-newly-diagnosed-or-recurrent-diffuse-midline-glioma-and-other-recurrent-brain-tumors/ Wed, 29 Apr 2026 15:08:21 +0000 https://clinicaltrials.eu/trial/study-of-onc206-for-children-and-young-adults-with-newly-diagnosed-or-recurrent-diffuse-midline-glioma-and-other-recurrent-brain-tumors/ This study examines the use of ONC206 in children and young adults with brain tumors, specifically Diffuse Midline Glioma and other returning cancerous brain tumors. Diffuse Midline Glioma is a type of aggressive brain tumor that grows in the middle structures of the brain, often in areas like the brainstem or thalamus, and has a specific genetic change called H3K27 alteration. The study also includes other types of returning cancerous tumors of the brain and spinal cord. ONC206 is a medication given by mouth that works by affecting certain parts of cells called mitochondria and by blocking specific receptors in the body. The medication comes as a powder that is mixed into a liquid solution for drinking.

The purpose of this study is to find the right dose of ONC206 that can be given safely to patients and to check whether the medication reaches the tumor tissue in the brain. The study is divided into different groups based on the type of tumor and previous treatments. Some patients will receive ONC206 alone, while others will receive it together with radiation therapy, which is a treatment that uses high-energy rays to target cancer cells. Some participants will receive ONC206 with a second course of radiation therapy if their tumor has grown back. There is also a part of the study that will measure how much of the medication gets into the tumor tissue by comparing it to the levels found in the blood before surgery.

During the study, patients will take ONC206 regularly and will have blood tests to check how the body processes the medication and to monitor for any side effects. Patients will also have imaging scans to see how the tumor responds to treatment. Some participants will need to provide tumor tissue samples that were collected during their standard medical care so researchers can study how the medication works in the tumor. The study will continue to monitor patients over time to gather information about safety and how well the treatment works.

]]> Study of Lenvatinib for Children and Young Adults with Relapsed or Refractory Solid Tumors, Including High Grade Glioma and Rhabdomyosarcoma https://clinicaltrials.eu/trial/study-of-lenvatinib-for-children-and-young-adults-with-relapsed-or-refractory-solid-tumors-including-high-grade-glioma-and-rhabdomyosarcoma/ Wed, 29 Apr 2026 14:28:16 +0000 https://clinicaltrials.eu/trial/study-of-lenvatinib-for-children-and-young-adults-with-relapsed-or-refractory-solid-tumors-including-high-grade-glioma-and-rhabdomyosarcoma/ This clinical trial is focused on studying the effects of a medication called lenvatinib in young patients who have certain types of cancer that have returned or are not responding to treatment. The cancers being studied include High Grade Glioma, Rhabdomyosarcoma, Ewing Sarcoma, and other solid tumors, except for osteosarcoma. The purpose of the study is to evaluate how well lenvatinib works in treating these cancers and to assess its safety in children, adolescents, and young adults.

Participants in the study will take lenvatinib in the form of a capsule, which is taken by mouth. The study will monitor the response of the tumors to the treatment over a period of time, specifically looking at the changes in the size of the tumors and any side effects experienced by the participants. The study aims to determine the effectiveness of lenvatinib in shrinking the tumors and improving the condition of the patients.

The study will last for several weeks, during which participants will receive regular check-ups and assessments to track their progress. The researchers will use specific criteria to evaluate the response of the tumors to the treatment, ensuring that the results are accurate and reliable. This study is an important step in finding better treatment options for young patients with these challenging types of cancer.

]]>